Singapore eDevelopment Limited
(Company Registration Number 200916763W)
7 *Temasek* Boulevard, #29-01B
Suntec Tower One, Singapore 038987

Impact BioMedical, Inc's Equivir performs well against a board range of viruses in testing by its Scientific Research Partner and preparations are underway for testing of Equivir against COVID-19

SINGAPORE, 2 March 2020 – Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) ("**SeD**") wishes to announce today that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("**GRDG**"), recently conducted an additional round of testing of Equivir, a patented medical treatment and preventative drug, against a broad range of viruses. The tests results revealed that Equivir performed well against a broad range of viruses and validates the results of previous laboratory testing conducted at multiple independent facilities. These tests demonstrate the ability of Equivir to control viruses responsible for deadly infectious diseases. The unique ability of Equivir to inhibit viruses makes it a promising candidate for the treatment of COVID-19, the disease caused by SARS-CoV-2 or severe acute respiratory syndrome coronavirus 2.

According to the U.S. Centers for Disease Control and Prevention or CDC, COVID-19 causes respiratory illnesses in people and can spread from person to person. SARS-CoV-2 was first identified in Wuhan, The People's Republic of China ("**China**"). As at 20 February 2020, the World Health Organisation reported 75,748 confirmed cases of COVID-19 of which China had 74,675 confirmed cases, although many estimate the numbers to be much higher.

GRDG had previously contracted multiple independent scientific research laboratories to test Equivir against a broad range of viruses including Influenza, Rhinovirus (one of the causes of the common cold) and Ebola. GRDG has recently conducted an additional round of testing of Equivir utilising the non-clinical and pre-clinical services program offered by the U.S. National Institute of Allergy and Infectious Diseases which is part of the U.S. National Institutes of Health. In this recent testing, Equivir demonstrated in vitro efficacy against multiple strains of Influenza (H1N1, H3N2, H5N1, H7N9, Influenza B and Parainfluenza 3), Human Rhinovirus-14, Human Coronavirus-A and Ebola. This recent testing validates the results of previous laboratory testing.

The research is headed by Mr. Daryl Thompson, GRDG's Director of Scientific Initiatives, who is an entrepreneur and biochemist known for multiple healthcare technology innovations. "*Equivir was designed as a solution for guidelines established by Project Bioshield,*" says Mr. Thompson. "*We are moving forward to establish Equivir as a potential therapeutic to mitigate COVID-19.*"

Mr. Chan Heng Fai, Executive Chairman, Executive Director and Chief Executive Officer of SeD, said, "*I am gratified to have this further validation on the technologies we have and we are excited to be able to contribute to the current situation in the best possible way we can.*".

GRDG's Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr. who was the former United States Assistant Surgeon General and the former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said that "*The ability of Equivir to be validated and quickly deployed is a solution to an issue that is of great interest to the global public health community.*".

GRDG is also advised by Lieutenant Colonel William H. Lyerly Jr., a retired U.S. Army Medical Service Corps Officer and a retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security. Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly states that "*this latest outbreak illustrates the speed at which pandemics can explode and the need for easily administered, effective, and versatile treatments. Equivir's potential to help treat and prevent illnesses caused by this and other future outbreaks is crucial for stopping the spread of the Coronavirus*".

Shareholders and potential investors of SeD Company should note that there is no certainty or assurance as at the date of this Press Release that Equivir will be licensed or close to monetisation. Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

End of Press Release

About Singapore eDevelopment Limited

Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.

For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About Impact BioMedical, Inc.

Impact BioMedical, Inc. ("**Impact BioMedical**") is a wholly-owned direct subsidiary of Global BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. Impact BioMedical strives to leverage its scientific know how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC. and Australian Exchange-listed Holista CollTech Limited, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases.

About GRDG Sciences, LLC.

GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson.

For more information, please visit: http://www.globalrdg.com.

This Press Release has been reviewed by the Company's Sponsor, Hong Leong Finance Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this Press Release, including the correctness of any of the statements or opinions made or reports contained in this Press Release.

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, Hong Leong Finance Limited, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, telephone (+65) 6415 9886.